Sign in
Stories
FDA Approval for Kamada's Cytogam Production
Share
Immunoglobulin Market Growth and Innovat...
Plasma Innovations and Human Generosity
Plasma Protein Therapeutics Market Expan...
ANJESO Drug Insight and Market Forecast
Advancements in Cancer Treatment and Mar...
Biosimilar Interleukins Market Growth
Overview
API
Kamada secures FDA approval to produce Cytogam in Israel after successful technology transfer from CSL Behring, aimed at prophylaxis of cytomegalovirus disease in organ transplant patients. The biopharmaceutical company plans to launch commercial manufacturing soon, expecting revenue growth from its FDA-approved IgG portfolio.
Ask a question
How could the increasing demand for advanced genetic disorder treatments affect the overall healthcare industry?
How might Kamada's FDA approval impact the competitive landscape of the plasma-derived therapy market?
What potential challenges could Kamada face in scaling up the production of Cytogam post-FDA approval?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage
biosp
pharm
prece
proth